Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.

Meier, Reinhard; Braren, Rickmer; Kosanke, Yvonne; Bussemer, Johanna; Neff, Frauke; Wildgruber, Moritz; Schwarzenböck, Sarah; Frank, Annette; Haller, Bernhard; Hohlbaum, Andreas M; Schwaiger, Markus; Gille, Hendrik; Rummeny, Ernst J; Beer, Ambros J

doi:10.1371/journal.pone.0094972

journal article

Document type:: Journal Article; Research Support, Non-U.S. Gov't
Author(s):: Meier, Reinhard; Braren, Rickmer; Kosanke, Yvonne; Bussemer, Johanna; Neff, Frauke; Wildgruber, Moritz; Schwarzenböck, Sarah; Frank, Annette; Haller, Bernhard; Hohlbaum, Andreas M; Schwaiger, Markus; Gille, Hendrik; Rummeny, Ernst J; Beer, Ambros J
Title:: Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.
Abstract:: Anticalins are a novel class of targeted protein therapeutics. The PEGylated Anticalin Angiocal (PRS-050-PEG40) is directed against VEGF-A. The purpose of our study was to compare the performance of diffusion weighted imaging (DWI), dynamic contrast enhanced magnetic resonance imaging (DCE)-MRI and positron emission tomography with the tracer [18F]fluorodeoxyglucose (FDG-PET) for monitoring early response to antiangiogenic therapy with PRS-050-PEG40. 31 mice were implanted subcutaneously with A673 rhabdomyosarcoma xenografts and underwent DWI, DCE-MRI and FDG-PET before and 2 days after i.p. injection of PRS-050-PEG40 (n = 13), Avastin (n = 6) or PBS (n = 12). Tumor size was measured manually with a caliper. Imaging results were correlated with histopathology. In the results, the tumor size was not significantly different in the treatment groups when compared to the control group on day 2 after therapy onset (P = 0.09). In contrast the imaging modalities DWI, DCE-MRI and FDG-PET showed significant differences between the therapeutic compared to the control group as early as 2 days after therapy onset (P<0.001). There was a strong correlation of the early changes in DWI, DCE-MRI and FDG-PET at day 2 after therapy onset and the change in tumor size at the end of therapy (r = -0.58, 0.71 and 0.67 respectively). The imaging results were confirmed by histopathology, showing early necrosis and necroptosis in the tumors. Thus multimodality multiparametric imaging was able to predict therapeutic success of PRS-050-PEG40 and Avastin as early as 2 days after onset of therapy and thus promising for monitoring early response of antiangiogenic therapy.
Journal title abbreviation:: PLoS ONE
Year:: 2014
Journal volume:: 9
Journal issue:: 5
Pages contribution:: e94972
Language:: eng
Fulltext / DOI:: doi:10.1371/journal.pone.0094972
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/24801709
Print-ISSN:: 1932-6203
TUM Institution:: Institut für Medizinische Statistik und Epidemiologie; Klinik und Poliklinik für Nuklearmedizin
BibTeX